Skip to content

Deferred costs at other companies

Phreesia logo
PhreesiaPHR

Other financials

Income statement

See full
Revenue$496.2M+2.6%
Gross profit$83.8M-18.2%
Operating income-$10.6M-553%
Net income-$26.6M+58.8%
EPS (diluted)-$0.24+61.9%

Balance sheet

See full
Cash & equivalents$142.0M-42.4%
Total debt$985.4M+13.3%
Total equity$396.4M-57.6%
Total assets$1.9B-29.2%

Cash flow

See full
Operating cash flow-$984.0K-122%

Valuation

See full
Market cap$565.78M-47.9%
Enterprise value$1.41B-17.6%
P/S0.3×-0.2×

Profitability

See full
Gross margin20.2%+4.9pp
Operating margin-22.2%-23.5pp
Net margin-26.3%-33.2pp
FCF margin-9.7%

Returns & leverage

See full
Return on equity-74.6%-90.1pp
Debt / equity2.5×+1.6×
Current ratio1.3×+0.3×

Where this comes from

Reported directly by Evolent Health, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CapitalizedContractCostNetNoncurrent.

The official record: Evolent Health, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Evolent Health, Inc.'s deferred costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Evolent Health, Inc.'s deferred costs?
Evolent Health, Inc. (EVH) reported deferred costs of $13.73M in Q1 2026.
How has Evolent Health, Inc.'s deferred costs changed year-over-year?
Evolent Health, Inc.'s deferred costs increased by 3.0% year-over-year, from $13.33M to $13.73M.
What is the long-term trend for Evolent Health, Inc.'s deferred costs?
Over 5 years (2020 to 2025), Evolent Health, Inc.'s deferred costs has grown at a -12.7% compound annual growth rate (CAGR), from $26.69M to $13.54M.